{'fraction_non_alphanumeric': 0.022274325908558032, 'fraction_numerical': 0.0011723329425556857, 'mean_word_length': 5.421052631578948, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Contrast-enhanced ultrasound (CEUS) in patients with chronic kidney disease (CKD)

Chronic kidney disease (CKD) affects over 8 million people in the United States and is a major risk factor for cardiovascular disease, hospitalization and death. Diagnosis is usually made with blood and urine tests, and imaging is used primarily to rule out obstruction or determine size. Blood and urine tests are also used to follow disease progression with imaging used only for specific situations. In this ongoing clinical study, we evaluate the feasibility of using microbubble contrast agents to perform contrast-enhanced ultrasound (CEUS) and develop qualitative and quantitative measures of perfusion in patients with CKD. CEUS imaging may provide information about kidney perfusion that will aid in early diagnosis, disease progression and response to therapy.